2026年4月1日 世界协调时23:31 / 路透社
节点运行失败
Item 1 of 2 2026年2月5日，美国华盛顿特区白宫园区南法院礼堂，美国总统唐纳德·特朗普在发布特朗普Rx药品折扣网站的活动上发表讲话。路透社/阿尔·德拉戈
[1/2]2026年2月5日，美国华盛顿特区白宫园区南法院礼堂，美国总统唐纳德·特朗普在发布特朗普Rx药品折扣网站的活动上发表讲话。路透社/阿尔·德拉戈 购买授权许可，将在新标签页打开
4月1日（路透社）——据彭博新闻周三援引知情人士报道，特朗普政府最快将于周四宣布对未达成确保美国低价药品协议的制药商征收关税。
白宫未立即回复路透社的置评请求。
订阅路透社健康周刊，获取最新医学突破与医疗趋势资讯。点击此处注册。
特朗普政府此前一直在考虑对进口品牌药和专利药征收100%关税，这促使全球制药商加大美国本土生产力度并增加库存。
广告 · 滚动继续阅读
辉瑞（PFE.N，将在新标签页打开）和阿斯利康（AZN.L，将在新标签页）已通过定价协议及对新特朗普Rx.gov平台的承诺，获得了多年关税豁免。礼来（LLY.N，将在新标签页）、强生（JNJ.N，将在新标签页）和默克（MRK.N，将在新标签页）已承诺投入数十亿美元扩大美国业务以规避处罚。
报道称，未达成协议且未与政府进行谈判的公司将被征收100%关税。
报道还称，相关计划尚未最终确定，仍有可能调整，部分药品和疾病类别也可能获得豁免。
法比奥拉·阿拉姆布罗 墨西哥城报道；克里斯·里斯 编辑
我们的报道准则：汤森路透信任原则，将在新标签页打开
Trump administration readies new tariffs on select drugmakers, Bloomberg News reports
April 1, 2026 11:31 PM UTC / Reuters
节点运行失败
Item 1 of 2 U.S. President Donald Trump speaks during an event to unveil the TrumpRx drug discount site, in the South Court Auditorium on the White House campus, in Washington, D.C., U.S., February 5, 2026. REUTERS/Al Drago
[1/2]U.S. President Donald Trump speaks during an event to unveil the TrumpRx drug discount site, in the South Court Auditorium on the White House campus, in Washington, D.C., U.S., February 5, 2026. REUTERS/Al Drago Purchase Licensing Rights, opens new tab
April 1 (Reuters) – The Trump administration is set to announce tariffs as soon as Thursday on drugmakers that have not struck deals guaranteeing low prices in the U.S., Bloomberg News reported on Wednesday, citing people familiar with the plan.
The White House did not immediately respond to Reuters’ request for comment.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
The Trump administration has been considering a 100% tariff on imported branded and patented medicines, prompting global drugmakers to ramp up U.S. manufacturing and stockpile inventory.
Advertisement · Scroll to continue
Pfizer (PFE.N), opens new tab and AstraZeneca (AZN.L), opens new tab have secured multi-year tariff exemptions through pricing deals and commitments to the new TrumpRx.gov platform. Eli Lilly (LLY.N), opens new tab, Johnson & Johnson (JNJ.N), opens new tab and Merck (MRK.N), opens new tab have pledged billions to expand U.S. operations to avoid penalties.
Companies that do not have agreements and are not in negotiations with the administration will be subject to 100% tariffs, the report said.
The plans are not final and could still change, and there could also be exemptions for some medicines and disease categories, it said.
Reporting by Fabiola Arámburo in Mexico City; Editing by Chris Reese
Our Standards: The Thomson Reuters Trust Principles., opens new tab
发表回复